Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 17/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.49 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.45 |
| ▸ | CALCA | P06881 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961629 | 0.95 | CALCRL (0.49) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3962029 | 0.91 | CALCRL (0.58) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3956604 | 0.91 | CALCRL (0.51) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3964340 | 0.90 | CALCRL (0.57) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3962033 | 0.90 | CALCRL (0.54) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3960238 | 0.88 | CALCRL (0.55) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3960475 | 0.88 | CALCRL (0.65) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3960870 | 0.86 | CALCRL (0.49) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3961262 | 0.86 | CALCRL (0.58) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL4174931 | 0.86 | CALCRL (0.59) | CALCRLCYP3A4RAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | claimed |
| EP-1517674-B1 | PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-04-11 | — | — | EP | claimed |
| EP-1769790-A1 | Preparations for the intranasal application of selected CGRP antagonists derived from amino acids | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | claimed |
| EP-1740175-A1 | USE OF A CGRP-ANTAGONIST COMBINED WITH A SEROTONIN-REUPTAKE INHIBITOR IN ORDER TO TREAT MIGRAINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20060193786-A1 | Pharmaceutical composition for intranasal administration containing a CGRP antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | claimed |
| WO-2005102322-A1 | USE OF A CGRP-ANTAGONIST COMBINED WITH A SEROTONIN-REUPTAKE INHIBITOR IN ORDER TO TREAT MIGRAINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20050233980-A1 | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| EP-1207884-B1 | USE OF CGRP ANTAGONISTS AND CGRP RELEASE INHIBITORS FOR CONTROLLING MENOPAUSAL HOT FLASHES | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-11-03 | — | — | EP | claimed |
| US-20040076587-A1 | Pharmaceutical composition for intranasal administration containing a CGRP antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-22 | — | — | US | claimed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1517674-B1 | PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-04-11 | — | — | EP | disclosed |
| EP-1769790-A1 | Preparations for the intranasal application of selected CGRP antagonists derived from amino acids | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| EP-1740175-A1 | USE OF A CGRP-ANTAGONIST COMBINED WITH A SEROTONIN-REUPTAKE INHIBITOR IN ORDER TO TREAT MIGRAINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| US-20040076587-A1 | Pharmaceutical composition for intranasal administration containing a CGRP antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004000289-A2 | PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-31 | — | — | WO | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | CALCRL 255/4885CYP3A4 1258/4885RAMP1 354/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CALCRL 276/4885CYP3A4 759/4885RAMP1 434/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | CALCRL 364/4885CYP3A4 564/4885RAMP1 459/4885 |
| US-20050233980-A1 | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine | SLC6A4, SLC6A2, HTR3B | CALCRL 26/4885CYP3A4 2585/4885RAMP1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.